ovtz20230331

0001437749-23-013198.txt : 20230509 0001437749-23-013198.hdr.sgml : 20230509 20230509120041 ACCESSION NUMBER: 0001437749-23-013198 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULUS VISIONTECH INC. CENTRAL INDEX KEY: 0001107280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061576391 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-29651 FILM NUMBER: 23900935 BUSINESS ADDRESS: STREET 1: 837 WEST HASTINGS STREET STREET 2: SUITE 507 CITY: VANCOUVER STATE: A1 ZIP: V6C 3N6 BUSINESS PHONE: 6046851017 MAIL ADDRESS: STREET 1: 837 WEST HASTINGS STREET STREET 2: SUITE 507 CITY: VANCOUVER STATE: A1 ZIP: V6C 3N6 FORMER COMPANY: FORMER CONFORMED NAME: OCULUS VISION TECH INC. DATE OF NAME CHANGE: 20120201 FORMER COMPANY: FORMER CONFORMED NAME: USA VIDEO INTERACTIVE CORP DATE OF NAME CHANGE: 20000217 10-Q 1 ovtz20230331_10q.htm FORM 10-Q ovtz20230331_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-29651

OCULUS VISIONTECH INC.

(Exact name of registrant as specified in its charter)

Wyoming	06-1576391
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

Suite 507 - 837 West Hastings Street, Vancouver, BC, Canada, V6C 3N6

(Address of principal executive offices) (Zip code)

(604) 685-1017

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” ‘‘accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large, accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☑
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☑

As at May 9, 2023, there were 91,422,469 shares of the registrant’s common stock outstanding

Table of Contents

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common
Common stock - no par value	OVTZ	Over The Counter Bulletin Board
Preferred stock - no par value	N/A	N/A
Common stock - no par value	OVT	TSX Venture Exchange
Common stock - no par value	USF1	Frankfurt Stock Exchange

Table of Contents

TABLE OF CONTENTS

		PART I – FINANCIAL INFORMATION
		Forward Looking Statements	4
Item 1.		Financial Statements	6
		Condensed Interim Consolidated Balance Sheets	6
	(A)	Condensed Interim Consolidated Statements of Operations and Comprehensive Loss	7
	(B)	Condensed Interim Consolidated Statements of Stockholders’ Equity	8
	(C)	Condensed Interim Consolidated Statements of Cash Flows	9
	(D)	Notes to Condensed Interim Consolidated Financial Statements	10
Item 2.	(E)	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.		Quantitative and Qualitative Disclosures About Market Risk	22
Item 4.		Controls and Procedures	22

		PART II – OTHER INFORMATION

Item 1.		Legal Proceedings	23
Item 1A.		Risk Factors	23
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.		Defaults Upon Senior Securities	23
Item 4.		Mine Safety Disclosure	23
Item 5.		Other Information	23
Item 6.		Exhibits	23

Table of Contents

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for the purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify these statements by forward-looking words such as “plan”, “may”, “will”, “expect”, “intend”, “anticipate”, believe”, “estimate” and “continue” or similar words. Forward-looking statements are statements that are not historical facts, and include, but are not limited to:

●

statements regarding our products and services, including:

	o	our digital watermarking technology and Cloud-based document protection system;
	o	our data privacy and data protection services and solutions; our technology, our cash needs, including our ability to fund our future capital expenditures and working capital requirements;
	o	our expectations regarding competition and growth in our sector; the future sources and availability of additional funding; and
	o	the effect of funding arrangements on projects and products.

You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as required by law.

Forward-looking statements are based on current expectations about future events affecting the Company and are subject to uncertainties and factors that affect all business operating in a global market as well as matters specific to the Company. These uncertainties and factors are difficult to predict, and many of them are beyond the Company’s control. Factors to consider when evaluating these forward-looking statements include, but are not limited to:

	●	the impact of pandemics;
	●	the Company’s limited operating history makes it difficult to evaluate its business and prospects;
	●	the Company has incurred substantial losses and expects to incur losses in the future and may never achieve profitability;
	●	if the Company is unable to obtain substantial additional financing, it may not be able to remain in business;
	●	the Company’s operating results in future periods are expected to be subject to significant fluctuations, which would likely affect the trading price of the Company’s common shares;
	●	the data privacy and data protection markets are highly competitive, and the Company’s failure to successfully compete will limit its ability to attain, retain and increase its market share;
	●	the document protection market is highly competitive, and the Company’s failure to compete successfully would limit its ability to retain and increase its market share;
	●	the video digital watermarking business is highly competitive, and the Company’s failure to compete successfully would limit its ability to retain and increase its market share;
	●	the Company is subject to rapid technological change, which could render its products and services obsolete;
	●	the Company is dependent upon vendors and other third-party service providers and will be competing with some of these companies;
	●	the Company’s services are technically complex, and it may not be able to prevent defects that could decrease their market acceptance, result in product liability, or harm its reputation;
	●	any loss of the Company’s personnel or inability to acquire new personnel could harm its business;
	●	a failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have material adverse effect on the Company’s business and operating results and shareholders could lose confidence in the Company’s financial reporting;
	●	the Company does not currently have any paying customers;
	●	the Company’s business may suffer if it cannot protect its intellectual property;
	●	the Company’s products may infringe the intellectual property rights of others, causing the Company to incur significant costs or prevent us from licensing its products;
	●	the Company’s success depends on the continued growth in demand for e-business applications;
	●	government regulation and legal uncertainties could add additional costs and risks to doing business on the Internet;
	●	the Company’s share price has been and could be highly volatile, which could result in substantial losses to investors;
	●	the Company has not paid cash dividends in the past and does not expect to pay cash dividends in the foreseeable future.

Table of Contents

Any return on investment may be limited to the value of the Company’s common shares;

	●	securities analysts may not initiate coverage or continue to cover the Company’s common shares, and this may have a negative impact on its market price;
	●	anti-takeover provisions in our charter documents could prevent or delay a change in control of the Company;
	●	the Company intends to issue additional equity securities, which may dilute the interests of current shareholders or carry rights or preferences senior to the common shares;
	●	the exercise of options and warrants and other issuances of common shares or securities convertible into or exercisable for common shares will dilute the ownership interest of the Company’s current shareholders and may adversely affect the future market price of the Company’s common shares;
	●	limited liability of executive officers and directors may discourage shareholders from bringing a lawsuit against them;
	●	requirements of the SEC with regard to low-priced “penny stocks” may adversely affect the ability of shareholders to sell their shares in the secondary market;
	●	the Company does not anticipate paying dividends to shareholders in the foreseeable future;
	●	the Company may be exposed to adverse currency exchange rate fluctuations, which could harm the Company’s financial results and cash flows;
	●	service outages and disruption of the Company’s infrastructure may harm the Company and adversely impact business operations and injure reputation;
	●	security vulnerabilities in the Company’s products and services or any breach of the Company’s security measures may injure its reputation and disrupt the Company’s business;
	●	the financial reporting obligations of being a public company in the United States are expensive, time consuming, and may place significant demands on the Company’s management; and
	●	the Company’s failure to manage or adequately address any one or more of these risks could result in the business suffering a material adverse effect.

The Company believes the items outlined above are important factors that could cause estimates included in its financial statements to differ materially from the actual results and those expressed in a forward-looking statement made in this report or elsewhere by the Company or on its behalf. The Company has discussed these factors in more detail under “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and other periodic reports filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this quarterly report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that the Company’s actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements. We do not intend to update our description of important factors each time a potential important factor arises, except as required by applicable securities laws and regulations. We advise our shareholders that they should (i) be aware that factors not referred to above could affect the accuracy of the Company’s forward-looking statements and (ii) use caution when considering the Company’s forward-looking statements.

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(Stated in US Dollars)

(Unaudited)



	31-Mar				December 31,
	2023				2022


ASSETS

Current Assets:
Cash and cash equivalents	$	529,692			$	687,602
Prepaid expenses and other current assets		13,728				30,238
Total Assets	$	543,420			$	717,840

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable and accrued expenses	$	302,206		#	$	276,585
Accounts payable and accrued expenses - related parties		25,841				25,838
Total current liabilities		328,047				302,423


Commitments and Contingencies		-				-

Stockholders' Equity:
Preferred stock - no par value; authorized 250,000,000 shares, none issued
Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 at December 31,2022 and March 31,2023		46,850,710				46,850,710
Additional paid-in capital		1,431,171				1,394,997
Accumulated other comprehensive income (loss)		(36,015	)			(34,856	)
Accumulated deficit		(48,030,493	)			(47,795,434	)
Stockholders' equity		215,373				415,417
Total Liabilities and Stockholders' Equity	$	543,420			$	717,840

SEE ACCOMPANYING NOTES

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Stated in US Dollars)

(Unaudited)



	For the three months ended
	March 31,			March 31,
	2023			2022
Revenue	$	-		$	-

Expenses:
Consulting		45,000			-
Research and development		84,203			345,463
Selling, general and administrative (Note 8)		72,777			96,253
Stock-based compensation (Note 7)		36,174			139,648

Total expenses		(238,154	)		(581,364	)

Interest income		3,095			-
Net loss		(235,059	)		(581,364	)

Other comprehensive loss
Currency translation differences		(1,159	)		(4,022	)

		(1,159	)		(4,022	)

Total comprehensive loss	$	(236,218	)	$	(585,386	)

Net loss per share - basic and diluted	$	(.00	)	$	(.01	)
Weighted-average number of common shares outstanding - basic and diluted		91,422,569			91,422,569

SEE ACCOMPANYING NOTES

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Stated in US Dollars)

(Unaudited)



	Common Stock
	Shares		Amount		Contribution Surplus		Commitment to Issue Shares		Accumulated Other Comprehensive Loss			Accumulated Deficit			Stockholders' Equity


Balance at December 31, 2022		91,422,569	$	46,850,710	$	1,394,997	$	-	$	(34,856	)	$	(47,795,434	)	$	415,417

Share-based compensation		-		-		36,174		-		-			-			36,174
Currency translation differences		-		-		-		-		(1,159	)		-			(1,159	)
Net loss		-		-		-		-		-			(235,059	)		(235,059	)

Balance at March 31, 2023		91,422,569	$	46,850,710	$	1,431,171	$	-	$	(36,015	)	$	(48,030,493	)	$	215,373



	Common Stock
	Shares		Amount		Contribution Surplus		Commitment to Issue Shares		Accumulated Other Comprehensive Loss			Accumulated Deficit			Stockholders' Equity


Balance at December 31, 2021		91,422,569	$	46,850,710	$	998,477	$	414,128	$	6,190		$	(46,145,845	)	$	2,123,660

Share-based compensation		-		-		139,648		-		-			-			139,648
Currency translation differences		-		-		-		-		(4,022	)		-			(4,022	)
Net loss		-		-		-		-		-			(581,364	)		(581,364	)

Balance at March 31, 2022		91,422,569	$	46,850,710	$	1,138,125	$	414,128	$	2,168		$	(46,727,209	)	$	1,677,922

SEE ACCOMPANYING NOTES

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Stated in US Dollars)

(Unaudited)



Three months ended March 31,	2023			2022

Cash flows from operating activities:
Net loss	$	(235,059	)	$	(581,364	)
Add back non-cash share-based compensation		36,174			139,648
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets		16,510			13,544
Increase (decrease) in accounts payable and accrued expenses		25,624			23,001
Increase (decrease) in accounts payable and accrued expenses due to related parties		-			1,616

Net cash used in operating activities		(156,751	)		(403,555	)


Effect of foreign currency translation		(1,159	)		(4,022	)

Net increase in cash and cash equivalents		(157,910	)		(407,577	)

Cash and cash equivalents at beginning of period		687,602			2,208,451

Cash and cash equivalents at end of period	$	529,692		$	1,800,874


Supplemental disclosures of cash flow information:

Cash paid during the period for interest	$	-		$	-
Cash paid during the period for income taxes	$	-		$	-

	$	-		$	-

There were no non-cash financing activities for the periods presented.

SEE ACCOMPANYING NOTES

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

1.	BASIS OF PRESENTATION AND BUSINESS

Oculus VisionTech, Inc. (the "Company") is a development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Substantially all of the Company's assets and substantially all its operations are located and conducted in the United States and Canada.

The unaudited condensed consolidated financial statements and notes herein should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the roles and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the SEC’s rules and regulations. Although management believes that the disclosures are adequate and make the information presented not misleading. In the opinion of management, all adjustments, which are of a normal and recurring nature (except as otherwise noted), that are necessary to present fairly the Company’s financial position as of March 31, 2023 and December 31, 2022, and its results of operation for the three months ended March 31, 2023 and 2022, and cash flows for the three months ended March 31, 2023 and 2022

2.	GOING CONCERN

These condensed interim consolidated financial statements are prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception and does not currently have the financial resources to sustain operations in the long-term. As shown in the financial statements, the Company has incurred a loss of $235,059 for the three months ended March 31, 2023 and, in addition the Company incurred losses of $1,649,589 for the year ended December 31, 2022. As of March 31, 2023, the Company had an accumulated deficit of $48,030,493 and working capital of $215,373. As a result of the Company’s current financial position and challenging access to capital, there can be no assurance that the Company will be able raise additional funds in the future, in which case the Company will be unable to meet its financial obligations. These material uncertainties raise substantial doubt upon the Company’s ability to continue as a going concern. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations as they come due which management believes it will be able to do. To date, the Company has funded operations primarily through the issuance of common stock and warrants to outside investors and the Company’s management. The Company believes that its operations will generate additional funds and that additional funding from outside investors and the Company’s management will continue to be available to the Company when needed.

There are many external factors that can adversely affect general workforces, economies and financial markets globally. Examples include, but are not limited to, the COVID-19 global pandemic and political conflict in other regions. It is not possible for the Company to predict the duration or magnitude of adverse results of such external factors and their effect on the Company’s business or ability to raise funds.

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of consolidation

These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.

Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

The controlled entities are listed in the following table:

Name of Subsidiary

Country of

Incorporation

Ownership

Interest at

March 31,

2023

Ownership

Interest at

December 31,

2022

Principal Activity

ComplyTrust Inc.

US/Delaware

100

Software Development

Significant judgments, estimates and assumptions

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:

Significant judgments

	●	the determination of functional currencies
	●	share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

Cash and cash equivalents

Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

Impairment of long-lived assets and long-lived assets to be disposed of

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

Research and development

Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at March 31, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

Intangible asset

Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.

Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

Income taxes

The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

Net loss per share

Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended March 31, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 5,415,000 ( December 31, 2022: 5,415,000) stock options and 17,400,000 ( December 31, 2022: 17,400,000) warrants were excluded from the calculation.

Right of use asset

The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right of use assets are subsequently amortized from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term using the straight line method.

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

Lease liability

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following payments during the lease term: fixed payments (including in-substance fixed payments), and the exercise price under a purchase option that the Company is reasonably certain to exercise.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising mainly if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option, or if there is a revised in substance fixed lease payment.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use asset, or is recorded in profit or loss if the carrying amount of the right of use asset has been reduced to zero.

Stock-based compensation

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.

The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

Functional currency

The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.

In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.

Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

Recently issued accounting pronouncements

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

4.	PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	March 31,		December 31,
	2023		2022

Prepaid expenses	$	12,076	$	28,028
Tax Receivable – Canadian GST		1,652		2,210
	$	13,728	$	30,238

5.	ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	March 31, 2023		December 31, 2022

Accounts payable	$	265,114	$	224,716
Accrued fees and expenses		37,092		51,869
	$	302,206	$	276,585

6.	COMMON STOCK

The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on March 31, 2023 and December 31, 2022.

The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.

As of March 31, 2023, there were 1,875,000 common shares held in escrow.

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

7.	STOCK OPTIONS

During the period ended March 31, 2023 and year ended December 31, 2022, the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares may be reserved for granting of stock options. All of the options granted vest 20% every six months.

However, all options will be considered vested if one of the following criteria are met by the Company:

i.	Meeting sales forecasts:

	-	The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.

ii.

the listing of the Company on any national securities exchange.

iii.

a Change of Control Event.

During the period ended March 31, 2023, the Company did not grant any stock options and recorded $36,174 share-based compensation for vested portion that were previously granted.

The changes in options are as follows:

	Number of options		Weighted average exercise price		Aggregate Intrinsic Value
Options outstanding, December 31, 2021		5,315,000	$	0.49	$	-
Granted		100,000		0.80		-
Options outstanding, December 31, 2022 and March 31, 2023		5,415,000	$	0.50	$	-

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at March 31, 2023.

Details of options outstanding as at March 31, 2023 are as follows:

Exercise price (CAD)		Number of options outstanding		Expiry date	Number of options exercisable		Remaining contractual life (years)

	$0.350		3,600,000	July 21, 2023		3,600,000		0.31
	$0.450		250,000	December 21, 2023		200,000		0.73
	$1.200		500,000	January 29, 2024		400,000		0.83
	$0.800		375,000	June 10, 2024		225,000		1.20
	$0.600		590,000	October 14, 2024		236,000		1.54
	$0.800		100,000	January 31, 2025		40,000		1.84

			5,415,000			4,701,000

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

8.	WARRANTS

The changes in warrants are as follows:

Number of

warrants

Weighted

average

exercise price

Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023

17,400,000

0.28

Details of warrants outstanding as at March 31, 2023 are as follows:

Exercise price				Number of warrants outstanding		Expiry date	Number of warrants exercisable		Remaining contractual life (years)

$	1.00		(CAD)		4,900,000	April 19, 2023⁽²⁾		4,900,000		0.05
$	0.001	⁽¹⁾	(USA)		12,500,000	June 4, 2025		-		2.18

					17,400,000			4,900,000

	(1)	No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.
	(2)	Expired subsequent to March 31, 2023

9.	SELLING, GENERAL AND ADMINISTRATIVE

The breakdown of selling, general and administrative for the period ended March 31, 2023 and 2022 is as follows:


	2023		2022

Filing and regulatory fees	$	12,577	$	22,447
Marketing		-		37,965
Professional fees		14,091		6,225
Rent		10,813		9,381
Office and administration		35,296		20,235

	$	72,777	$	96,253

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 and 2022

(Stated in US Dollars)

(Unaudited)

10.

RESEARCH AND DEVELOPMENT

The breakdown of research and development for the period ended March 31, 2023 and 2022 is as follows:


	2023		2022

Project management	$	84,203	$	11,990
Software development		49,765		269,250
Business development		3,952		32,451
Payroll		30,486		31,772

	$	84,203	$	345,463

11.

RELATED PARTIES

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

The Company defines its key management as the Board of Directors, Chief Executive Officer, President, and Chief Financial Officer. Remuneration of directors and key management personnel of the Company for the period ended March 31, 2023 and 2022 was as follows:


	2023		2022

Consulting	$	45,000	$	-
Selling general and administrative		15,369		27,493
Share-based compensation to directors and officers		1,442		17,431
	$	61,811	$	44,924

The Company for the period ended March 31, 2023 and 2022 reimbursed a related party $15,369 and $27,493, respectively, for selling, general and administrative expenses paid on behalf of the Company. The Company also recorded share-based compensation of $1,442 (2022 - $17,431) for options vested to related parties during the period ended March 31, 2023 and 2022.

12.

FINANCIAL INSTRUMENTS AND RISKS

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are described below.

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Table of Contents

OCULUS VISIONTECH INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022 and 2021

(Stated in US Dollars)

Fair value of financial instruments

The Company has various financial instruments including cash and cash equivalents, accounts payable and accrued expenses, and accounts payable and accrued expenses – related parties. The carrying values of accounts payable and accrued expenses and accounts payable and accrued expenses – related parties approximate their fair values due to the short-term nature of these financial instruments.

Cash and cash equivalents is carried at a level 1 fair value measurement.

The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:

Credit risk

The Company is exposed to credit risk only with respect to uncertainties as to timing and amount of collectability of receivables. The Company believes its credit risk is low because receivables is comprised of goods and services tax (GST) which is recoverable from the governing body in Canada. Management does not believe the receivables are impaired. The Company doesn’t believe there is significant credit risk associated with cash as these amounts are held with major Canadian banks.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at March 31, 2023, the Company had a cash and cash equivalents balance of $529,692 ( December 31, 2022 – $687,602) to settle current liabilities of $328,047 ( December 31, 2022 – $302,423). All of the Company’s financial liabilities have contractual maturities of 30 days or due on demand and are subject to normal trade terms.

Interest rate risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize such a loss is limited as it does not have any significant interest-bearing financial instruments.

Foreign currency risk

As at March 31, 2023 and December 31, 2022, the Company is exposed to foreign currency risk as certain monetary financial instruments are denominated in Canadian currency. The Company’s sensitivity analysis suggests that reasonably expected changes in the rates of exchange in the United States would change foreign exchange gain or loss by an insignificant amount.

13.

OPERATING LEASES

The Company has one operating lease with unrelated third parties for office space at Vancouver, Canada.

The lease at the Vancouver, Canada location is on a month-to-month basis with monthly rental payments of $3,950 (CND). For the period ended March 31, 2023 and 2022 rent expense was $10,305 and $8,874, respectively.

14.

SEGMENTED INFORMATION

The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and United States.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS AND SUPPLEMENTARY DATA

The following discussion should be read in conjunction with our condensed interim financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements under applicable securities laws. You can identify these statements by forward-looking words such as “plan”, “may”, “will”, “expect”, “intend”, “anticipate”, believe”, “estimate” and “continue” or similar words. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, statements regarding our products and services, including our digital watermarking technology and Cloud-based document protection system, our data privacy and data protection services and solutions, our technology, our cash needs, including our ability to fund our future capital expenditures and working capital requirements, and our expectations regarding competition and growth in our sector, are forward looking statements, the future sources and availability of additional funding, and the effect of funding arrangements on projects and products. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as required by law.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and other periodic reports filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this quarterly report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that the Company’s actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements.

OVERVIEW OF THE COMPANY

Oculus VisionTech Inc. (OVTZ) is a Canadian-based development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Headquartered in Vancouver, British Columbia, Canada, the company was originally founded by image processing experts and is operated by experienced leadership. Currently, OVTZ is expanding and investing in a suite of new data protection and data privacy security products that will revolutionize CCPA, GDPR, LGPD and other data privacy legislation compliance for both data subjects and data controllers worldwide. Our mission is innovation of viable software tools that enable intelligent automated solutions for public cloud customer services and needs specific to data privacy and data protection for individuals, organizations and their customers worldwide, through a vision of mutually trusted data compliance.

Our Forget-Me-Yes® data privacy product is a Software-as-a-Service (SaaS) platform developed to specifically address the global ‘Right-to-be-Forgotten’ (RtbF) and Right-of-Erase (RoE) legal components of Brazil’s LGPD, Europe’s GDPR, California Consumer Privacy Act (CCPA), Colorado Privacy Act (CPA) and Virginia CDPA data privacy regulatory compliance. An additional new data protection software tool, ComplyScan®, is being developed to address public cloud data governance compliance. Our legacy Cloud Document Protection System (Cloud-DPS) technology leveraged our digital watermarking technology to enable OVTZ to offer a SaaS-based document management platform for tamper-proof document authentication and protection. Historically, we have used our digital watermarking technology for streaming video content distribution based on embedded digital watermarking, as well as video-on-demand (VOD) systems, services and source-to-destination digital media delivery solutions that allow live or recorded digitized and compressed video to be transmitted through Internet, intranet, satellite or wireless connectivity.

We were incorporated on April 18, 1986, as "First Commercial Financial Group Inc." in the Province of Alberta, Canada. In 1989, our name was changed to "Micron Metals Canada Corp.", which purchased 100% of the outstanding shares of USA Video Inc., a Texas corporation, in order to focus on the digital media business. In 1995, we changed our name to "USA Video Interactive Corp." and continued out of the Province of Alberta into the State of Wyoming. At a shareholders meeting held on December 30, 2011, a resolution was passed to change our name to "Oculus VisionTech Inc." and to alter our share capital by way of a reverse stock split (share consolidation) on the basis of fifteen old common shares for one new common share. On January 25, 2012, we changed our name to "Oculus VisionTech Inc." In June 2020, OVTZ acquired OCL Technologies Inc. (OCL), a Delaware corporation data privacy software development startup based in San Diego, California. As a 100% wholly-owned subsidiary of OVTZ and to better align with customer and market focus, OCL has completed a corporate name change to ComplyTrust® Inc. (CTI) on January 21, 2021. All OCL references throughout this document are synonymous with the new name change, CTI.

Table of Contents

Our executive and corporate headquarter offices are located at Suite 507, 837 West Hastings Street, Vancouver, British Columbia, Canada, V6C 3N6. Our telephone number is 1-800-684-0183 and our facsimile number is 604-685-5777. Our email address is contact@ovtz.com and our website is www.ovtz.com. Our common shares are listed for trading on the TSX Venture Exchange (TSX.V – OVT, OTCQB – OVTZ, FSE – USF1).

BUSINESS OBJECTIVES:

In this age of digital transformation, data monetization, IoT, and massive data migration to converged hyperscale, geo-disbursed Cloud infrastructure and workloads, data protection and data privacy have taken center stage. GDPR, LGPD, CCPA, and many other new international (Canada/PIPEDA, China/PIPL, India/DIA) and upcoming US Federal (ADPPA) and individual State data privacy regulations enable individuals and organizations the right to access and request deletion of all personal information for a given data subject. In our ever increasing Everything-as-a-Service world, OVTZ recognizes the need for global cloud-native data privacy and data protection solutions that are multi-cloud platform-ready and can augment both existing legacy and newer agile-driven architectures. OVTZ is building modular microservices-based software solutions and services for both hybrid on-premise and multi-cloud data management that incorporate automated malware, privacy and ransomware scanning, reporting and visualization.

Our new Forget-Me-Yes® (FMY) Software-as-a-Service (SaaS) data privacy solution is a secure, Zero-Knowledge platform providing a single-source capability of continuous ‘right-to-be-forgotten’ (RtbF) and ‘right-of-erase’ (RoE) privacy compliance by incorporating automated policy-driven re-query services that guarantees a Data Subject’s requested RtbF/RoE data remains ‘forgotten’ over the life of their FMY subscription. FMY incorporates hybrid encryption technology that ensures all User Interface, data-in-transit and data-at-rest remain secure and can only be accessed by the subscriber. With a cloud-native architecture, the FMY functionality can be utilized as either a complete turnkey SaaS subscription platform, or individually licensed for seamless integration with existing 3rd. party applications and data privacy platforms.

Our new ComplyTrust® Software-as-a-Service Suite (CTSS) is a set of software tools specifically designed to address cloud-native data management and regulatory compliant data governance. CTSS will help to remove enterprise organizational barriers and blockers to further enable successful cloud migration and deployment that benefit the cloud infrastructure providers, enterprise organizations, and users collectively. CTSS helps to automate and visualize cloud compliance reporting across accounts, regions and services based on a variety of user-definable and data driven metrics. Development of the first CTSS product, a cloud-native data backup compliance reporting tool called ComplyScan® (CS), has commenced.

OVTZ had recognized that cloud-based, digital document security/protection products were a potentially viable business opportunity for the Company that allowed us to apply our proprietary real-time digital video watermarking technology, originally developed for studios and networks in the entertainment industry, to the digital document security/protection market. Cloud-DPS secures and protects digital documents (including text documents, photos, blueprints, etc.) from any modification, and/or attempted forgery by imperceptibly watermarking documents, using real-time image processing and watermarking algorithms, embedded into a secured/protected copy of a document. This authentication and verification process ensures the integrity of the original digital document.

Our near-term business objectives for the above:

1.	Patent and license new technology developed within the corporate research and development program;

Demonstrate proof of concept on selected commercial projects with our Forget-Me-Yes® (FMY) data privacy Software-as-a-Service platform and ComplyTrust® SaaS Suite (CTSS), gain industry recognition for the architectural and business differentiators of the company product’s FMY data privacy, ComplyScan® (CS) compliance validation tool and our legacy C-DPS authentication/tamper-proof functionality, and generate sales and support revenues in FY21+.

Table of Contents

CRITICAL ACCOUNTING POLICIES (AND ESTIMATES)

In preparing its consolidated financials statement, the Company follows GAAP, which is described in Note 3, Summary of Significant Accounting Policies, to the Company’s December 31, 2022 Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K. The application of these principles requires significant judgements or an estimation process that can affect the results of operations, financial position and cash flows of the Company, as well as the related footnote disclosures. The Company continually reviews its accounting policies and financials information disclosures. Except as noted in Note 3, Summary of Significant Accounting Policies, of the Company’s financials statements, there have been no material changes in the Company’s critical accounting policies or estimates since December 31, 2022.

RESULTS OF OPERATIONS

Sales

Sales for the three-month period ended March 31, 2023 and 2022 were $nil.

Cost of Sales

The cost of sales for the three-month period ended March 31, 2023 and 2022 were $nil.

Selling, General and Administrative Expenses

Selling, general and administrative expenses, consisting of product marketing expenses, consulting fees, office, professional fees and other expenses to execute our business plan and for our day-to-day operations, increased in the year ended December 31, 2022. We continue to develop and market C-DPS – Cloud Document Protection System and the “Right-to-be-Forgotten” and “Right-to-Erase” platform. Administrative expenses have decreased/increased moderately as a result of insignificant fluctuations in general costs.

Selling, general and administrative expenses for the period ended March 31, 2023 decreased to $72,777 from $96,253 for the period ended March 31, 2022. We incurred decreased costs during the period due to minimal corporate and filing activities during the fiscal year.

We have arranged for additional staff and consultants to engage in marketing activities in an effort to identify and assess appropriate market segments, develop business arrangements with prospective partners, create awareness of new products and services, and communicate to the industry and potential customers. Other components of selling, general and administrative expenses did not change significantly.

Research and Development

Research and development for the period ended March 31, 2023 decreased to $84,203 from $345,463 for the comparable period in 2023. This was a result of the Company’s effort to reduce costs due to the minimal activity during the period. We incurred comparable costs in 2022 as the management maintain its decision in 2021, to develop CTSS (ComplyScan®) as well as the on-going development of our subsidiary’s Forget-Me-Yes® zero trust data privacy platform. (“Right-to-be-Forgotten” and “Right-to-Erase”).

Net Losses

To date, we have not achieved profitability and expect to incur substantial losses for the foreseeable future. Our net loss for the three months ended March 31, 2023 was $235,059, compared with a net loss of $581,364 for the comparative period. Our total comprehensive loss for the three months ended March 31, 2023 was $236,218, compared with a comprehensive loss of $558,386, which includes currency translation differences of $1,159.

Table of Contents

Liquidity and Capital Resources

At March 31, 2023 our cash and cash equivalents position was $529,692, a decrease from $687,602 at December 31, 2022. We had a working capital of $215,373 and an accumulated deficit of $48,030,493 at March 31, 2023.

We have historically satisfied our capital needs primarily by shareholders’ loans and issuing equity securities to our officers, directors, employees and a small group of investors, and from short-term bridge loans from members of management.

As of March 31, 2023, we had $529,692 in cash and cash equivalents. Management has forecasted the Company will not have sufficient working capital to operate for the ensuing 12 months. We will require an additional $3 million to $5 million to finance operations for the fiscal 2023 and we intend to obtain such financing through sales of our equity securities. While the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing, or that such financing will be on terms acceptable to the Company, to meet future operational needs which may result in the delay, reduction, or discontinuation of ongoing development programs.

Assuming the aforementioned $3 million to $5 million in financing is obtained, continuing operations for the longer-term will be supported through anticipated growth in revenues and through additional sales of our securities. Although longer-term financing requirements may vary depending upon our sales performance, management expects that we will require additional financing of $3 million to $5 million for fiscal 2023. We have no binding commitments or arrangements for additional financing, and there is no assurance that management will be able to obtain any additional financing on terms acceptable to us, if at all.

OFF-BALANCE SHEET ARRANGEMENTS

As of March 31, 2023, we have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Oculus is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information required under this Item.

Item 4. Controls and Procedures.

We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, who is our principal executive officer, and Chief Financial Officer, who is our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

As of March 31, 2023, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting for the quarterly period ended March 31, 2023, identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15, that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

Item 1A.

Risk Factors.

Oculus is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide information required under this Item. A description of the risks associated with our business, financial condition, and results of operations is set forth in Part I, Item 1A, of our Annual Report on Form 10 -K for the fiscal year ended December 31, 2022 filed with the SEC on March 28, 2023. Those factors continue to be meaningful for your evaluation of Oculus and we urge you to review and consider the risk factors presented in such Form 10-K.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

The information required by this Item is set forth on the exhibit index which follows the signature page of this report.

Exhibit No.		Description

EX-31.1		Certification of CEO

EX-31.2		Certification of CFO

EX-32.1		SOX Certifiaction of CEO

EX-32.2		SOC Certification of CFO

101.INS	Inline XBRL Instance Document

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	OCULUS VISIONTECH INC.

May 9, 2023	By:	/s/ Rowland Perkins
		Rowland Perkins
		President and Chief Executive Officer
		(principal executive officer)


May 9, 2023	By:	/s/ Anton J. Drescher
		Anton J. Drescher
		Chief Financial Officer
		(principal financial and accounting officer)

EX-31.1 2 ex_513793.htm EXHIBIT 31.1 ex_513793.htm

EXHIBIT 31.1

CERTIFICATION

I, Rowland Perkins, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Oculus VisionTech Inc..;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2023

By:

/s/ Rowland Perkins

Rowland Perkins

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_513794.htm EXHIBIT 31.2 ex_513794.htm

EXHIBIT 31.2

CERTIFICATIONS

I, Anton J. Drescher, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Oculus VisionTech Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2023

By:

/s/ Anton J. Drescher

Anton J. Drescher

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1 4 ex_513795.htm EXHIBIT 32.1 ex_513795.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Oculus VisionTech Inc. (the “Company”), for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rowland Perkins, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: May 9, 2023

By:

/s/ Rowland Perkins

Rowland Perkins

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 ex_513796.htm EXHIBIT 32.2 ex_513796.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Oculus VisionTech Inc. (the “Company”), for the period ended March 31, 2023 , as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anton J. Drescher , Chief Financial Officer for the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: May 9, 2023

By:

/s/ Anton J. Drescher

Anton J. Drescher

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-101.SCH 6 ovtz-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation and Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Common Stock link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stock Options link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Warrants link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Selling, General and Administrative link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Research and Development link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Financial Instruments and Risks link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Operating Leases link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Segmented Information link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Stock Options (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Selling, General and Administrative (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 10 - Research and Development (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 6 - Common Stock (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stock Options (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 10 - Research and Development - Research and Development (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 13 - Operating Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 ovtz-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ovtz-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ovtz-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 3 - Summary of Significant Accounting Policies Note 4 - Prepaid Expenses and Other Current Assets Note 5 - Accounts Payable and Accrued Expenses Note 7 - Stock Options Note 8 - Warrants Note 9 - Selling, General and Administrative Note 10 - Research and Development Note 11 - Related Parties Accumulated other comprehensive income (loss) Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Foreign Currency Transactions and Translations Policy [Policy Text Block] Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Note 7 - Stock Options - Changes in Options (Details) Add back non-cash share-based compensation Lessee, Leases [Policy Text Block] us-gaap_LiabilitiesCurrent Liabilities, Current Total current liabilities Note 7 - Stock Options - Details of Options Outstanding (Details) Note 8 - Warrants - Schedule of Warrants (Details) Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Note 10 - Research and Development - Research and Development (Details) Note 11 - Related Parties - Related Party Expenses (Details) Earnings Per Share, Policy [Policy Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] Revenue Income Tax, Policy [Policy Text Block] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Currency translation differences Currency translation differences Research and Development Expense, Policy [Policy Text Block] Other comprehensive loss us-gaap_SharesIssued Balance (in shares) Balance (in shares) Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Granted, aggregate intrinsic value (in dollars per share) Number of options exercisable (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Remaining contractual life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Options outstanding, aggregate intrinsic value Tax Receivable – Canadian GST Interest income Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 at December 31,2022 and March 31,2023 Exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average exercise price (in dollars per share) Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Common stock, shares issued (in shares) Common stock, no par value (in dollars per share) Common Stock, No Par Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Granted, weighted average exercise price (in dollars per share) Lessee, Operating Leases [Text Block] us-gaap_AccountsPayableCurrent Accounts payable Ownership [Domain] Number of options outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options outstanding (in shares) Options outstanding (in shares) Ownership [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued (in shares) Cash paid during the period for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Prepaid expenses Cash paid during the period for income taxes Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Preferred stock, no par value (in dollars per share) Goodwill and Intangible Assets, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Accrued fees and expenses us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Financial Instruments Disclosure [Text Block] Current Liabilities: Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Supplemental disclosures of cash flow information: us-gaap_Assets Total Assets Plan Name [Axis] Plan Name [Domain] Consulting The aggregate costs incurred for consultation. Other Assets Disclosure [Text Block] Rent Operating Lease, Expense ovtz_WorkingCapitalDeficit Working Capital (Deficit) Represents the amount of difference between Current Assets and Current Liabilities. Statement [Line Items] Commitment to Issue Shares [Member] Represents commitment to issue shares. Additional paid-in capital Share-Based Payment Arrangement [Text Block] AOCI Attributable to Parent [Member] Stockholders' Equity: Segment Reporting Disclosure [Text Block] Award Type [Domain] Net loss us-gaap_NetIncomeLoss Net Income (Loss) Attributable to Parent Net loss Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period ASSETS Effect of foreign currency translation us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase in cash and cash equivalents Commitments and Contingencies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Share-Based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Warrant [Member] us-gaap_PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Range Six [Member] Represents the range six. Employee Stock Option, Expiration Date of August 1, 2024 [Member] Represents the Employee Stock Option, Expiration Date of August 1, 2024. Nonrelated Party [Member] us-gaap_CostsAndExpenses Total expenses Expenses: Retained Earnings [Member] Consulting Fees [Member] Represents consulting fees paid. Increase (decrease) in accounts payable and accrued expenses Related party transactions Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions [Table Text Block] Employee Stock Option, Expiration Date of July 21, 2023 [Member] Represents stock option with an expiration date of July 21, 2023. Equity Components [Axis] Equity Component [Domain] Exercise price (in CAD per share) us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrants outstanding (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Reimbursement [Member] Represents the related party transaction for reimbursement. Office and administration Vancouver, CA Operating Lease [Member] Represents the operating lease for the Vancouver, Candada location. ovtz_OperatingLeasesMonthlyRentExpense Operating Leases, Monthly Rent Expense Amount of monthly rent expense incurred under the operating lease. Increase (decrease) in accounts payable and accrued expenses due to related parties Vesting Every Six Months [Member] Represents the options vested every 6 months. Cash and cash equivalents us-gaap_CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value Stock-based compensation (Note 7) Share-Based Payment Arrangement, Expense Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_ComprehensiveIncomeNetOfTax Total comprehensive loss Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Related Party [Member] Related and Nonrelated Party Status [Domain] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Related and Nonrelated Party Status [Axis] Current Fiscal Year End Date Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Decrease (increase) in prepaid expenses and other current assets Selling, General and Administrative Disclosure [Text Block] The entire disclosure for selling, general and administrative expenses. Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Schedule of Selling, General and Administrative Expenses [Table Text Block] Tabular disclosure of selling, general and administrative expenses. Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Entity File Number Entity Emerging Growth Company Document Type Filing and regulatory fees Expenditures for filing and regulatory. Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Share-based compensation Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Statement [Table] ComplyTrust Inc. Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted-average number of common shares outstanding - basic and diluted (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code Net loss per share - basic and diluted (in dollars per share) Entity Address, State or Province Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] EX-101.PRE 10 ovtz-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 pic1.jpg begin 644 pic1.jpg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htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2023	May 09, 2023
Document Information [Line Items]
Entity Central Index Key	0001107280
Entity Registrant Name	OCULUS VISIONTECH INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	0-29651
Entity Incorporation, State or Country Code	WY
Entity Tax Identification Number	06-1576391
Entity Address, Address Line One	Suite 507 - 837 West Hastings Street
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6C 3N6
City Area Code	604
Local Phone Number	685-1017
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		91,422,469

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 529,692	$ 687,602
Prepaid expenses and other current assets	13,728	30,238
Total Assets	543,420	717,840
Current Liabilities:
Accounts payable and accrued expenses	302,206	276,585
Total current liabilities	328,047	302,423
Commitments and Contingencies
Stockholders' Equity:
Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 at December 31,2022 and March 31,2023	46,850,710	46,850,710
Additional paid-in capital	1,431,171	1,394,997
Accumulated other comprehensive income (loss)	(36,015)	(34,856)
Accumulated deficit	(48,030,493)	(47,795,434)
Stockholders' equity	215,373	415,417
Total Liabilities and Stockholders' Equity	543,420	717,840
Nonrelated Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	302,206	276,585
Related Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	$ 25,841	$ 25,838

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	250,000,000	250,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	91,422,569	91,422,569
Common stock, shares outstanding (in shares)	91,422,569	91,422,569

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 0	$ 0
Expenses:
Consulting	45,000	0
Research and development	84,203	345,463
Selling, general and administrative (Note 8)	72,777	96,253
Stock-based compensation (Note 7)	36,174	139,648
Total expenses	(238,154)	(581,364)
Interest income	3,095	0
Net loss	(235,059)	(581,364)
Other comprehensive loss
Currency translation differences	(1,159)	(4,022)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(1,159)	(4,022)
Total comprehensive loss	$ (236,218)	$ (585,386)
Net loss per share - basic and diluted (in dollars per share)	$ (0)	$ (1)
Weighted-average number of common shares outstanding - basic and diluted (in shares)	91,422,569	91,422,569

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Commitment to Issue Shares [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	91,422,569
Balance at Dec. 31, 2021	$ 46,850,710	$ 998,477	$ 414,128	$ 6,190	$ (46,145,845)	$ 2,123,660
Share-based compensation	0	139,648	0	0	0	139,648
Currency translation differences	0	0	0	(4,022)	0	(4,022)
Net loss	$ 0	0	0	0	(581,364)	(581,364)
Balance (in shares) at Mar. 31, 2022	91,422,569
Balance at Mar. 31, 2022	$ 46,850,710	1,138,125	414,128	2,168	(46,727,209)	1,677,922
Balance (in shares) at Dec. 31, 2021	91,422,569
Balance at Dec. 31, 2021	$ 46,850,710	998,477	414,128	6,190	(46,145,845)	2,123,660
Net loss						(1,649,589)
Balance (in shares) at Dec. 31, 2022	91,422,569
Balance at Dec. 31, 2022	$ 46,850,710	1,394,997	0	(34,856)	(47,795,434)	415,417
Share-based compensation	0	36,174	0	0	0	36,174
Currency translation differences	0	0	0	(1,159)	0	(1,159)
Net loss	$ 0	0	0	0	(235,059)	(235,059)
Balance (in shares) at Mar. 31, 2023	91,422,569
Balance at Mar. 31, 2023	$ 46,850,710	$ 1,431,171	$ 0	$ (36,015)	$ (48,030,493)	$ 215,373

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Net loss	$ (235,059)	$ (581,364)	$ (1,649,589)
Add back non-cash share-based compensation	36,174	139,648
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	16,510	13,544
Increase (decrease) in accounts payable and accrued expenses	25,624	23,001
Increase (decrease) in accounts payable and accrued expenses due to related parties	0	1,616
Net cash used in operating activities	(156,751)	(403,555)
Effect of foreign currency translation	(1,159)	(4,022)
Net increase in cash and cash equivalents	(157,910)	(407,577)
Cash and cash equivalents at beginning of period	687,602	2,208,451	2,208,451
Cash and cash equivalents at end of period	529,692	1,800,874	$ 687,602
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	$ 0	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Business

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.	BASIS OF PRESENTATION AND BUSINESS

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

2.	GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Significant Accounting Policies [Text Block]

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of consolidation

These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On May 9, 2023, the Board approved the condensed interim consolidated financial statements dated March 31, 2023.

These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.

Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.

The controlled entities are listed in the following table:

Name of Subsidiary

Country of

Incorporation

Ownership

Interest at

March 31,

2023

Ownership

Interest at

December 31,

2022

Principal Activity

ComplyTrust Inc.

US/Delaware
100
%
100
%

Software Development

Significant judgments, estimates and assumptions

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:

Significant judgments

●

the determination of functional currencies

●

share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

Cash and cash equivalents

Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

Impairment of long-lived assets and long-lived assets to be disposed of

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

Research and development

Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at March 31, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

Intangible asset

Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.

Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

Income taxes

The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

Net loss per share

Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended March 31, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 5,415,000 ( December 31, 2022: 5,415,000) stock options and 17,400,000 ( December 31, 2022: 17,400,000) warrants were excluded from the calculation.

Right of use asset

The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right of use assets are subsequently amortized from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term using the straight line method.

Lease liability

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following payments during the lease term: fixed payments (including in-substance fixed payments), and the exercise price under a purchase option that the Company is reasonably certain to exercise.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising mainly if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option, or if there is a revised in substance fixed lease payment.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use asset, or is recorded in profit or loss if the carrying amount of the right of use asset has been reduced to zero.

Stock-based compensation

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.

The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

Functional currency

The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.

In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.

Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

Recently issued accounting pronouncements

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Other Assets Disclosure [Text Block]

4.	PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	March 31,		December 31,
	2023		2022

Prepaid expenses	$	12,076	$	28,028
Tax Receivable – Canadian GST		1,652		2,210
	$	13,728	$	30,238

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5.	ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	March 31, 2023		December 31, 2022

Accounts payable	$	265,114	$	224,716
Accrued fees and expenses		37,092		51,869
	$	302,206	$	276,585

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Common Stock

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Equity [Text Block]

6.	COMMON STOCK

The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on March 31, 2023 and December 31, 2022.

The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.

As of March 31, 2023, there were 1,875,000 common shares held in escrow.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Options

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

7.	STOCK OPTIONS

However, all options will be considered vested if one of the following criteria are met by the Company:

i.	Meeting sales forecasts:

	-	The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.

ii.

the listing of the Company on any national securities exchange.

iii.

a Change of Control Event.

During the period ended March 31, 2023, the Company did not grant any stock options and recorded $36,174 share-based compensation for vested portion that were previously granted.

The changes in options are as follows:

	Number of options		Weighted average exercise price		Aggregate Intrinsic Value
Options outstanding, December 31, 2021		5,315,000	$	0.49	$	-
Granted		100,000		0.80		-
Options outstanding, December 31, 2022 and March 31, 2023		5,415,000	$	0.50	$	-

Details of options outstanding as at March 31, 2023 are as follows:

Exercise price (CAD)		Number of options outstanding		Expiry date	Number of options exercisable		Remaining contractual life (years)

	$0.350		3,600,000	July 21, 2023		3,600,000		0.31
	$0.450		250,000	December 21, 2023		200,000		0.73
	$1.200		500,000	January 29, 2024		400,000		0.83
	$0.800		375,000	June 10, 2024		225,000		1.20
	$0.600		590,000	October 14, 2024		236,000		1.54
	$0.800		100,000	January 31, 2025		40,000		1.84

			5,415,000			4,701,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Warrants

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Class of Warrant or Right [Text Block]

8.	WARRANTS

The changes in warrants are as follows:

Number of

warrants

Weighted

average

exercise price

Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023

17,400,000

0.28

Details of warrants outstanding as at March 31, 2023 are as follows:

Exercise price				Number of warrants outstanding		Expiry date	Number of warrants exercisable		Remaining contractual life (years)

$	1.00		(CAD)		4,900,000	April 19, 2023⁽²⁾		4,900,000		0.05
$	0.001	⁽¹⁾	(USA)		12,500,000	June 4, 2025		-		2.18

					17,400,000			4,900,000

	(1)	No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.
	(2)	Expired subsequent to March 31, 2023

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Selling, General and Administrative

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Selling, General and Administrative Disclosure [Text Block]

9.	SELLING, GENERAL AND ADMINISTRATIVE

The breakdown of selling, general and administrative for the period ended March 31, 2023 and 2022 is as follows:


	2023		2022

Filing and regulatory fees	$	12,577	$	22,447
Marketing		-		37,965
Professional fees		14,091		6,225
Rent		10,813		9,381
Office and administration		35,296		20,235

	$	72,777	$	96,253

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Research and Development

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Research, Development, and Computer Software Disclosure [Text Block]

10.

RESEARCH AND DEVELOPMENT

The breakdown of research and development for the period ended March 31, 2023 and 2022 is as follows:


	2023		2022

Project management	$	84,203	$	11,990
Software development		49,765		269,250
Business development		3,952		32,451
Payroll		30,486		31,772

	$	84,203	$	345,463

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Related Parties

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

11.

RELATED PARTIES

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.


	2023		2022

Consulting	$	45,000	$	-
Selling general and administrative		15,369		27,493
Share-based compensation to directors and officers		1,442		17,431
	$	61,811	$	44,924

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Financial Instruments and Risks

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Financial Instruments Disclosure [Text Block]

12.

FINANCIAL INSTRUMENTS AND RISKS

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Fair value of financial instruments

Cash and cash equivalents is carried at a level 1 fair value measurement.

The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:

Credit risk

Liquidity risk

Interest rate risk

Foreign currency risk

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Operating Leases

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

13.

OPERATING LEASES

The Company has one operating lease with unrelated third parties for office space at Vancouver, Canada.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 14 - Segmented Information

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

14.

SEGMENTED INFORMATION

The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and United States.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Basis of consolidation

The controlled entities are listed in the following table:

Name of Subsidiary

Country of

Incorporation

Ownership

Interest at

March 31,

2023

Ownership

Interest at

December 31,

2022

Principal Activity

ComplyTrust Inc.

US/Delaware

100

Software Development

Use of Estimates, Policy [Policy Text Block]

Significant judgments, estimates and assumptions

Significant judgments

	●	the determination of functional currencies
	●	share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of long-lived assets and long-lived assets to be disposed of

Research and Development Expense, Policy [Policy Text Block]

Research and development

Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible asset

The useful lives of intangible assets are assessed as either finite or indefinite.

Income Tax, Policy [Policy Text Block]

Income taxes

Earnings Per Share, Policy [Policy Text Block]

Net loss per share

Lessee, Leases [Policy Text Block]

Right of use asset

Lease liability

Share-Based Payment Arrangement [Policy Text Block]

Stock-based compensation

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Functional currency

New Accounting Pronouncements, Policy [Policy Text Block]

Recently issued accounting pronouncements

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]

Name of Subsidiary

Country of

Incorporation

Ownership

Interest at

March 31,

2023

Ownership

Interest at

December 31,

2022

Principal Activity

ComplyTrust Inc.

US/Delaware

100

Software Development

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	March 31,		December 31,
	2023		2022

Prepaid expenses	$	12,076	$	28,028
Tax Receivable – Canadian GST		1,652		2,210
	$	13,728	$	30,238

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 5 - Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	March 31, 2023		December 31, 2022

Accounts payable	$	265,114	$	224,716
Accrued fees and expenses		37,092		51,869
	$	302,206	$	276,585

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Options (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of options		Weighted average exercise price		Aggregate Intrinsic Value
Options outstanding, December 31, 2021		5,315,000	$	0.49	$	-
Granted		100,000		0.80		-
Options outstanding, December 31, 2022 and March 31, 2023		5,415,000	$	0.50	$	-

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise price (CAD)		Number of options outstanding		Expiry date	Number of options exercisable		Remaining contractual life (years)

	$0.350		3,600,000	July 21, 2023		3,600,000		0.31
	$0.450		250,000	December 21, 2023		200,000		0.73
	$1.200		500,000	January 29, 2024		400,000		0.83
	$0.800		375,000	June 10, 2024		225,000		1.20
	$0.600		590,000	October 14, 2024		236,000		1.54
	$0.800		100,000	January 31, 2025		40,000		1.84

			5,415,000			4,701,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 8 - Warrants (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Warrants or Right [Table Text Block]

Number of

warrants

Weighted

average

exercise price

Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023

17,400,000

0.28

Exercise price				Number of warrants outstanding		Expiry date	Number of warrants exercisable		Remaining contractual life (years)

$	1.00		(CAD)		4,900,000	April 19, 2023⁽²⁾		4,900,000		0.05
$	0.001	⁽¹⁾	(USA)		12,500,000	June 4, 2025		-		2.18

					17,400,000			4,900,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 9 - Selling, General and Administrative (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Selling, General and Administrative Expenses [Table Text Block]


	2023		2022

Filing and regulatory fees	$	12,577	$	22,447
Marketing		-		37,965
Professional fees		14,091		6,225
Rent		10,813		9,381
Office and administration		35,296		20,235

	$	72,777	$	96,253

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 10 - Research and Development (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Research and Development Expenses [Table Text Block]


	2023		2022

Project management	$	84,203	$	11,990
Software development		49,765		269,250
Business development		3,952		32,451
Payroll		30,486		31,772

	$	84,203	$	345,463

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 11 - Related Parties (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables


	2023		2022

Consulting	$	45,000	$	-
Selling general and administrative		15,369		27,493
Share-based compensation to directors and officers		1,442		17,431
	$	61,811	$	44,924

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Net Income (Loss) Attributable to Parent	$ (235,059)	$ (581,364)	$ (1,649,589)
Retained Earnings (Accumulated Deficit)	(48,030,493)		$ (47,795,434)
Working Capital (Deficit)	$ 215,373

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details Textual) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	5,415,000	5,415,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	17,400,000	17,400,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)	Mar. 31, 2023	Dec. 31, 2022
ComplyTrust Inc. [Member]
ComplyTrust Inc.	100.00%	100.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Prepaid expenses	$ 12,076	$ 28,028
Tax Receivable – Canadian GST	1,652	2,210
Prepaid Expense and Other Assets, Current	$ 13,728	$ 30,238

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accounts payable	$ 265,114	$ 224,716
Accrued fees and expenses	37,092	51,869
Accounts Payable and Accrued Liabilities, Current	$ 302,206	$ 276,585

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 6 - Common Stock (Details Textual) - $ / shares $ / shares in Thousands	Mar. 31, 2023	Dec. 31, 2022
Common Stock, No Par Value (in dollars per share)	$ 0	$ 0
Common Stock, Shares Authorized (in shares)	500,000,000	500,000,000
Common Stock, Shares, Outstanding, Ending Balance (in shares)	91,422,569	91,422,569
Preferred Stock, Shares Authorized (in shares)	250,000,000	250,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Common Stock, Shares Held in Escrow (in shares)	1,875,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Options (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
Note 7 - Stock Options (Details Textual) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			100,000
Share-Based Payment Arrangement, Expense	$ 36,174	$ 139,648
Rolling Stock Option Plan [Member]
Share-based Compensation Arrangement, Percent of Issued and Outstanding Common Shares Reserved	10.00%
Rolling Stock Option Plan [Member] \| Employee Stock Option, Expiration Date of August 1, 2024 [Member] \| Vesting Every Six Months [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	20.00%
Rolling Stock Option Plan [Member] \| Employee Stock Option, Expiration Date of July 21, 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0
Share-Based Payment Arrangement, Expense	$ 36,174
Rolling Stock Option Plan [Member] \| Employee Stock Option, Expiration Date of July 21, 2023 [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	20.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Options - Changes in Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Dec. 31, 2020
Options outstanding (in shares)	5,315,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.49
Options outstanding, aggregate intrinsic value		$ 0	$ 0
Granted, options (in shares)	100,000
Granted, weighted average exercise price (in dollars per share)	$ 0.80
Granted, aggregate intrinsic value (in dollars per share)	$ 0

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Options - Details of Options Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2020
Exercise price (in dollars per share)	$ 0.50	$ 0.49
Number of options outstanding (in shares)	5,415,000	5,315,000
Number of options exercisable (in shares)	4,701,000
Range One [Member]
Exercise price (in dollars per share)	$ 0.350
Number of options outstanding (in shares)	3,600,000
Number of options exercisable (in shares)	3,600,000
Remaining contractual life (Year)	3 months 21 days
Range Two [Member]
Exercise price (in dollars per share)	$ 0.450
Number of options outstanding (in shares)	250,000
Number of options exercisable (in shares)	200,000
Remaining contractual life (Year)	8 months 23 days
Range Three [Member]
Exercise price (in dollars per share)	$ 1.200
Number of options outstanding (in shares)	500,000
Number of options exercisable (in shares)	400,000
Remaining contractual life (Year)	9 months 29 days
Range Four [Member]
Exercise price (in dollars per share)	$ 0.800
Number of options outstanding (in shares)	375,000
Number of options exercisable (in shares)	225,000
Remaining contractual life (Year)	1 year 2 months 12 days
Range Five [Member]
Exercise price (in dollars per share)	$ 0.600
Number of options outstanding (in shares)	590,000
Number of options exercisable (in shares)	236,000
Remaining contractual life (Year)	1 year 6 months 14 days
Range Six [Member]
Exercise price (in dollars per share)	$ 0.800
Number of options outstanding (in shares)	100,000
Number of options exercisable (in shares)	40,000
Remaining contractual life (Year)	1 year 10 months 2 days

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 8 - Warrants - Schedule of Warrants (Details)

3 Months Ended

Mar. 31, 2023

$ / shares

Mar. 31, 2023

$ / shares

Warrants outstanding (in shares)

17,400,000

Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares

$ 0.28

Number of warrants exercisable (in shares)

4,900,000

Warrants Expiring on April 19, 2023 [Member]

Warrants outstanding (in shares)

4,900,000

Exercise price (in CAD per share) | $ / shares

$ 1.00

Number of warrants exercisable (in shares)

4,900,000

Remaining contractual life (Year)

18 days

Warrants Expiring on June 4, 2025 [Member]

Warrants outstanding (in shares)

12,500,000

Exercise price (in CAD per share) | $ / shares

$ 0.001

^[1]

Remaining contractual life (Year)

2 years 2 months 4 days

[1]	No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI's 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Filing and regulatory fees	$ 12,577	$ 22,447
Marketing	0	37,965
Professional fees	14,091	6,225
Rent	10,813	9,381
Office and administration	35,296	20,235
Selling, General and Administrative Expense	$ 72,777	$ 96,253

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 10 - Research and Development - Research and Development (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Project management	$ 84,203	$ 11,990
Software development	49,765	269,250
Business development	3,952	32,451
Payroll	30,486	31,772
Research and Development Expense	$ 84,203	$ 345,463

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 11 - Related Parties (Details Textual) - USD ($)	3 Months Ended
Note 11 - Related Parties (Details Textual) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Related Party Transaction, Amounts of Transaction	$ 61,811	$ 44,924
Share-based Compensation [Member]
Related Party Transaction, Amounts of Transaction	1,442	17,431
Reimbursement [Member]
Related Party Transaction, Amounts of Transaction	$ 15,369	$ 27,493

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 11 - Related Parties - Related Party Expenses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Related party transactions	$ 61,811	$ 44,924
Consulting Fees [Member]
Related party transactions	45,000	0
Selling, General and Administrative Expenses [Member]
Related party transactions	15,369	27,493
Share-based Compensation [Member]
Related party transactions	$ 1,442	$ 17,431

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 12 - Financial Instruments and Risks (Details Textual) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value	$ 529,692	$ 687,602
Liabilities, Current	$ 328,047	$ 302,423

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 13 - Operating Leases (Details Textual)	3 Months Ended
Note 13 - Operating Leases (Details Textual)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 CAD ($)	Mar. 31, 2022 USD ($)
Operating Lease, Expense	$ 10,813		$ 9,381
Vancouver, CA Operating Lease [Member]
Operating Leases, Monthly Rent Expense		$ 3,950
Operating Lease, Expense	$ 10,305		$ 8,874

XML 57 ovtz20230331_10q_htm.xml IDEA: XBRL DOCUMENT 0001107280 2023-01-01 2023-03-31 0001107280 2023-05-09 0001107280 2023-03-31 0001107280 2022-12-31 0001107280 us-gaap:NonrelatedPartyMember 2023-03-31 0001107280 us-gaap:NonrelatedPartyMember 2022-12-31 0001107280 us-gaap:RelatedPartyMember 2023-03-31 0001107280 us-gaap:RelatedPartyMember 2022-12-31 0001107280 2022-01-01 2022-03-31 0001107280 us-gaap:CommonStockMember 2022-12-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001107280 ovtz:CommitmentToIssueSharesMember 2022-12-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001107280 us-gaap:RetainedEarningsMember 2022-12-31 0001107280 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001107280 ovtz:CommitmentToIssueSharesMember 2023-01-01 2023-03-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001107280 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001107280 us-gaap:CommonStockMember 2023-03-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001107280 ovtz:CommitmentToIssueSharesMember 2023-03-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001107280 us-gaap:RetainedEarningsMember 2023-03-31 0001107280 us-gaap:CommonStockMember 2021-12-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001107280 ovtz:CommitmentToIssueSharesMember 2021-12-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001107280 us-gaap:RetainedEarningsMember 2021-12-31 0001107280 2021-12-31 0001107280 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001107280 ovtz:CommitmentToIssueSharesMember 2022-01-01 2022-03-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001107280 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001107280 us-gaap:CommonStockMember 2022-03-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001107280 ovtz:CommitmentToIssueSharesMember 2022-03-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001107280 us-gaap:RetainedEarningsMember 2022-03-31 0001107280 2022-03-31 0001107280 2022-01-01 2022-12-31 0001107280 ovtz:ComplytrustIncMember 2023-03-31 0001107280 ovtz:ComplytrustIncMember 2022-12-31 0001107280 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001107280 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001107280 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001107280 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001107280 ovtz:RollingStockOptionPlanMember 2023-03-31 0001107280 ovtz:EmployeeStockOptionExpirationDateOfAugust12024Member ovtz:RollingStockOptionPlanMember ovtz:VestingEverySixMonthsMember 2023-01-01 2023-03-31 0001107280 ovtz:EmployeeStockOptionExpirationDateOfJuly212023Member ovtz:RollingStockOptionPlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-03-31 0001107280 ovtz:EmployeeStockOptionExpirationDateOfJuly212023Member ovtz:RollingStockOptionPlanMember 2023-01-01 2023-03-31 0001107280 2020-12-31 0001107280 2021-01-01 2021-12-31 0001107280 ovtz:RangeOneMember 2023-03-31 0001107280 ovtz:RangeOneMember 2023-01-01 2023-03-31 0001107280 ovtz:RangeTwoMember 2023-03-31 0001107280 ovtz:RangeTwoMember 2023-01-01 2023-03-31 0001107280 ovtz:RangeThreeMember 2023-03-31 0001107280 ovtz:RangeThreeMember 2023-01-01 2023-03-31 0001107280 ovtz:RangeFourMember 2023-03-31 0001107280 ovtz:RangeFourMember 2023-01-01 2023-03-31 0001107280 ovtz:RangeFiveMember 2023-03-31 0001107280 ovtz:RangeFiveMember 2023-01-01 2023-03-31 0001107280 ovtz:RangeSixMember 2023-03-31 0001107280 ovtz:RangeSixMember 2023-01-01 2023-03-31 0001107280 ovtz:WarrantsExpiringOnApril192023Member 2023-03-31 0001107280 ovtz:WarrantsExpiringOnApril192023Member 2023-01-01 2023-03-31 0001107280 ovtz:WarrantsExpiringOnJune42025Member 2023-03-31 0001107280 ovtz:WarrantsExpiringOnJune42025Member 2023-01-01 2023-03-31 0001107280 ovtz:ConsultingFeesMember 2023-01-01 2023-03-31 0001107280 ovtz:ConsultingFeesMember 2022-01-01 2022-03-31 0001107280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001107280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001107280 ovtz:SharebasedCompensationMember 2023-01-01 2023-03-31 0001107280 ovtz:SharebasedCompensationMember 2022-01-01 2022-03-31 0001107280 ovtz:ReimbursementMember 2023-01-01 2023-03-31 0001107280 ovtz:ReimbursementMember 2022-01-01 2022-03-31 0001107280 ovtz:VancouverCAOperatingLeaseMember 2023-01-01 2023-03-31 0001107280 ovtz:VancouverCAOperatingLeaseMember 2022-01-01 2022-03-31 thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y iso4217:CAD shares iso4217:CAD 0001107280 OCULUS VISIONTECH INC. false --12-31 Q1 2023

250000000

500000000

91422569

-0

500000000

91422569

1.00

0.001

10-Q true 2023-03-31 false 0-29651 WY 06-1576391 Suite 507 - 837 West Hastings Street Vancouver BC CA V6C 3N6 604 685-1017 Yes Yes Non-accelerated Filer true false false 91422469

529692

687602

13728

30238

543420

717840

302206

276585

25841

25838

328047

302423

46850710

1431171

1394997

-36015

-34856

-48030493

-47795434

215373

415417

543420

717840

45000 0

84203

345463

72777

96253

36174

139648

238154

581364

3095

-235059

-581364

-1159

-4022

-1159

-4022

-236218

-585386

-1

91422569

46850710

1394997

-34856

-47795434

415417

36174

-1159

-235059

91422569

46850710

1431171

-36015

-48030493

215373

91422569

46850710

998477

414128

6190

-46145845

2123660

139648

-4022

-581364

91422569

46850710

1138125

414128

2168

-46727209

1677922

-235059

-581364

36174

139648

-16510

-13544

25624

23001

1616

-156751

-403555

-1159

-4022

-157910

-407577

687602

2208451

529692

1800874

-235059

-1649589

-48030493

215373

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.6%;"> 3. </td><td style="vertical-align:top;width:auto;"> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </td></tr> </tbody></table> Basis of consolidation These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On May 9, 2023, the Board approved the condensed interim consolidated financial statements dated March 31, 2023. These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated. The controlled entities are listed in the following table: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-top: 1px solid black; border-bottom: 1px solid black;"> Name of Subsidiary </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-top: 1px solid black; border-bottom: 1px solid black;"> Country of Incorporation </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at December 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> Principal Activity </td></tr> <tr style="vertical-align: bottom;"><td style="width: 21%; text-align: center;"> </td><td style="width: 20%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 23%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"> ComplyTrust Inc. </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);"> US/Delaware </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> Software Development </td></tr> </tbody></table> Significant judgments, estimates and assumptions The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows. The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following: Significant judgments <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> the determination of functional currencies </td></tr> <tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information. </td></tr> </tbody></table> Cash and cash equivalents Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. Impairment of long-lived assets and long-lived assets to be disposed of Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell. Research and development Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at March 31, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed. Intangible asset Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss. Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired. Income taxes The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Net loss per share Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended March 31, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 5,415,000 ( December 31, 2022: 5,415,000) stock options and 17,400,000 ( December 31, 2022: 17,400,000) warrants were excluded from the calculation. Right of use asset The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right of use assets are subsequently amortized from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term using the straight line method. Lease liability The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Lease payments included in the measurement of the lease liability comprise the following payments during the lease term: fixed payments (including in-substance fixed payments), and the exercise price under a purchase option that the Company is reasonably certain to exercise. The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising mainly if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option, or if there is a revised in substance fixed lease payment. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use asset, or is recorded in profit or loss if the carrying amount of the right of use asset has been reduced to zero. Stock-based compensation The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement. The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant. Functional currency The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar. In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss. Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss. Recently issued accounting pronouncements The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

Basis of consolidation These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On May 9, 2023, the Board approved the condensed interim consolidated financial statements dated March 31, 2023. These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated. The controlled entities are listed in the following table: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-top: 1px solid black; border-bottom: 1px solid black;"> Name of Subsidiary </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-top: 1px solid black; border-bottom: 1px solid black;"> Country of Incorporation </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at December 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> Principal Activity </td></tr> <tr style="vertical-align: bottom;"><td style="width: 21%; text-align: center;"> </td><td style="width: 20%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 23%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"> ComplyTrust Inc. </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);"> US/Delaware </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> Software Development </td></tr> </tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-top: 1px solid black; border-bottom: 1px solid black;"> Name of Subsidiary </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-top: 1px solid black; border-bottom: 1px solid black;"> Country of Incorporation </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> Ownership Interest at December 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> Principal Activity </td></tr> <tr style="vertical-align: bottom;"><td style="width: 21%; text-align: center;"> </td><td style="width: 20%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 23%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"> ComplyTrust Inc. </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);"> US/Delaware </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> % </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23%; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> Software Development </td></tr> </tbody></table>

Significant judgments, estimates and assumptions The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows. The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following: Significant judgments <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> the determination of functional currencies </td></tr> <tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information. </td></tr> </tbody></table>

Cash and cash equivalents Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

Impairment of long-lived assets and long-lived assets to be disposed of Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

Research and development Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at March 31, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

Intangible asset Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss. Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

Income taxes The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

Net loss per share Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended March 31, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 5,415,000 ( December 31, 2022: 5,415,000) stock options and 17,400,000 ( December 31, 2022: 17,400,000) warrants were excluded from the calculation.

5415000

17400000

Right of use asset The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right of use assets are subsequently amortized from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term using the straight line method. Lease liability The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Lease payments included in the measurement of the lease liability comprise the following payments during the lease term: fixed payments (including in-substance fixed payments), and the exercise price under a purchase option that the Company is reasonably certain to exercise. The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising mainly if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option, or if there is a revised in substance fixed lease payment. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use asset, or is recorded in profit or loss if the carrying amount of the right of use asset has been reduced to zero.

Stock-based compensation The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement. The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

Functional currency The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar. In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss. Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

Recently issued accounting pronouncements The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> March 31, </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> December 31, </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Prepaid expenses </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,076</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,028</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Tax Receivable – Canadian GST </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,652</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,210</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,728</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table>

12076

28028

1652

2210

13728

30238

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2022 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Accounts payable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">265,114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">224,716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Accrued fees and expenses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,092</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,869</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">302,206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">276,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>

265114

224716

37092

51869

302206

276585

500000000

91422569

250000000

1875000

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.6%;"> 7. </td><td style="vertical-align:top;width:auto;"> STOCK OPTIONS </td></tr> </tbody></table> During the period ended March 31, 2023 and year ended December 31, 2022, the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares may be reserved for granting of stock options. All of the options granted vest 20% every six months. However, all options will be considered vested if one of the following criteria are met by the Company: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> i. </td><td colspan="2" rowspan="1" style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Meeting sales forecasts: </td></tr> <tr><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: auto; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">-</td><td style="width: auto; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ii. </td><td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> the listing of the Company on any national securities exchange. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> iii. </td><td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> a Change of Control Event. </td></tr> </tbody></table> During the period ended March 31, 2023, the Company did not grant any stock options and recorded $36,174 share-based compensation for vested portion that were previously granted. The changes in options are as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Number of options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted average exercise price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Options outstanding, December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,315,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.49</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.80</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Options outstanding, December 31, 2022 and March 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,415,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at March 31, 2023. Details of options outstanding as at March 31, 2023 are as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Exercise price (CAD) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Number of options outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black; border-top: 1px solid black;"> Expiry date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Number of options exercisable </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Remaining contractual life (years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$0.350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,600,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> July 21, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,600,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> December 21, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.73</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$1.200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> January 29, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">400,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.83</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">375,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> June 10, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">225,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.600</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">590,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> October 14, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">236,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">$0.800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"> January 31, 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">40,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">1.84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 17%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">5,415,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 18%; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">4,701,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 18%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> </tbody></table>

0.10

0.20

36174

5315000

0.49

100000

0.80

5415000

0.50

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Exercise price (CAD) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Number of options outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black; border-top: 1px solid black;"> Expiry date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Number of options exercisable </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black; border-top: 1px solid black;"> Remaining contractual life (years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$0.350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,600,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> July 21, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,600,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> December 21, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.73</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$1.200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> January 29, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">400,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.83</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">375,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> June 10, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">225,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$0.600</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">590,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> October 14, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">236,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 17%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">$0.800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"> January 31, 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">40,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">1.84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 17%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 17%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">5,415,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 18%; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">4,701,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 18%; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> </tbody></table>

0.350

3600000

P0Y3M21D

0.450

250000

200000

P0Y8M23D

1.200

500000

400000

P0Y9M29D

0.800

375000

225000

P1Y2M12D

0.600

590000

236000

P1Y6M14D

0.800

100000

40000

P1Y10M2D

5415000

4701000

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align:top;width:6.6%;"> 8. </td> <td style="vertical-align:top;width:auto;"> WARRANTS </td> </tr> </tbody> </table> The changes in warrants are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> Number of warrants </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 68%; border-bottom: 1px solid rgb(0, 0, 0);"> Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023 </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,400,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.28</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table> Details of warrants outstanding as at March 31, 2023 are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Exercise price </td><td style="font-family: Times New Roman; font-size: 10pt; width: 2%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Number of warrants outstanding </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Expiry date </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Number of warrants exercisable </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Remaining contractual life (years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 2%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 18%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.00</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> (CAD) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%;"> April 19, 2023(2) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.05</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.001</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1) </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> (USA) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> June 4, 2025 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 2%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 18%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 2%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,400,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> (1) </td> <td style="width: auto;"> No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control. </td> </tr> <tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> (2) </td> <td style="width: auto;"> Expired subsequent to March 31, 2023 </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> Number of warrants </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 68%; border-bottom: 1px solid rgb(0, 0, 0);"> Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023 </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,400,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.28</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Exercise price </td><td style="font-family: Times New Roman; font-size: 10pt; width: 2%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Number of warrants outstanding </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Expiry date </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Number of warrants exercisable </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> Remaining contractual life (years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 2%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 18%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.00</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> (CAD) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%;"> April 19, 2023(2) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.05</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.001</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1) </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> (USA) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> June 4, 2025 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 2%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 15%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 18%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 2%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,400,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,900,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> </tbody></table>

17400000

0.28

4900000

4900000 P0Y18D

12500000

P2Y2M4D

17400000

4900000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.6%;"> 9. </td><td style="vertical-align:top;width:auto;"> SELLING, GENERAL AND ADMINISTRATIVE </td></tr> </tbody></table> The breakdown of selling, general and administrative for the period ended March 31, 2023 and 2022 is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Filing and regulatory fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,447</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Marketing </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,091</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Rent </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Office and administration </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">72,777</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Filing and regulatory fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,447</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Marketing </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,091</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Rent </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Office and administration </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">72,777</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 12577 22447

37965

14091

6225

10813

9381

35296

20235

72777

96253

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Project management </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84,203</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,990</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> Software development </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,765</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">269,250</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> Business development </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,952</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,451</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Payroll </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,486</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,772</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84,203</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">345,463</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 84203 11990

49765

269250

3952 32451 30486 31772

84203

345463

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Consulting </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">45,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> Selling general and administrative </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,369</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,493</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Share-based compensation to directors and officers </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,431</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">61,811</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,924</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table>

45000

15369

27493

1442

17431

61811

44924

15369

27493

1442

17431

529692

687602

328047

302423

3950

10305

8874

No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI's 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-8?20$3;8T.P6BP^0"X99K>]9!:G3B:VVO*&V3]URQ7<66O3, >79C.QK>&L MMEO.72,G=#J=3QHF5/;A_;ZMI9G$%]KQR@FMH- 7?!?\V?YWWU^2)V'%@Y#" MO2RR\%WRC#1"B4:\\GJ133-BM_KY;VW$JU:.R55EM)2++.]N?.?&B>J@>.4A MO[$'&TH<>_C* &21S:?0X%H8ZT*-T#X#QB<.E;NKG=.?A'3M4)M M?#/P%)/H,4(<]I]=$"_-[X11K]>BXC>ZVC5VK MD"M5DX_*09#(G>J:@KK^2>&O[^KNJ1W@1C$TEP)NF+LZ@!\/\EJKFBO+:T"# MH(F&0(G54M3 4Y,(DB*0](20/VD$62"0Q2DABPBR1"#+4T*6$>0,@9R=$G(6 M04?^8E98HM=D:;B%WX2J\<0Y0R#/$D!2@+S5D 5]&"MN MXLQSCK"=)V K@&VU:QIF7GP(5V*C!/R>*1=!7B"0%PD@2X"$SFV9@#S^J_5# MTQ(&2?T^SN%3+(E/$V#. /.JJO1..4N6[(4!0\"\BC%1UQQ9-@%S#IC7NFE@ MDJRX',P:F1P\,$TI^ M9*,$L L?-BXE))D_R"U7W#!Y./0PI>1'=DJ7KJ? ^16R-#/5-O#=\"W'#'A(PS>X$)J$BQM1G-[/&Q2H$)J#BI@.*#E0(3 M4'%2 ?6BB1ZEG51 /4Q,0$4* ?U_/_OO#(K/@ I,0$4* 0UX/L@*.!8*=*@/96UMCS^&W^RUK.O4)7I M4)_C_M#$WN54G>.\V*?4?#@7U_MP*F._;L+Y=F5;MZZ-N$_$^OM]K .G_7Z^Q3.Z8_![J=NCW$?0BIZJ[+=A30O MW*5ZGH[N?I#^;7+16V[F1;O<2.%R!RD$:?X@@R#+'^0AR.BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'I; M9[.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&^/>GL"O3WJ[0GT M]JBW)]#;H]Z>0&_?V>PFT-NCWOZ=>L=TK4)\]CS6^/QW4IUN]X;GX^_+Q\G. M"W7'V<'OL<4O4$L#!!0 ( !)@J593V2LIL@$ %,; 3 6T-O;G1E M;G1?5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W; M4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4 MA)U7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\; MLK;,:+!0UK^H.E2Q;<6H?K_=!VUX K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " 2 M8*E6F5R<(Q & "<)P $P @ ', 0 >&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( !)@J58K6/ZXB@4 ",= 8 M " @0T( !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ $F"I5N%9$^ZZ @ TP@ !@ M ("!_1( 'AL+W=OT5 !X;"]W;W)K MV(% "C'P M& @(&6&@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ $F"I5ASG/03K! IQ, !@ ("!+B 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I5KGQ MN5P+#P RRD !@ ("!_2L 'AL+W=O&UL4$L! A0#% @ M$F"I5H(7*:>N @ V04 !D ("!.SX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I5M&PO=V]R:W-H M965T&UL4$L! M A0#% @ $F"I5F19ZY"6 @ AP4 !D ("!5ET 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I M5CAT,2V4 @ A 4 !D ("!<7, 'AL+W=O&PO=V]R:W-H965T)X !X;"]W;W)K M&UL4$L! A0#% @ $F"I5O$"TZ[- @ 1P8 M !D ("!>WP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I5JHYR=R- @ ;P4 !D M ("!#(4 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ $F"I5O[-?1$= @ #P4 !D ("!WHT 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I5LG] MLXRX @ (@@ !D ("!.I4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ $F"I5@PGL2OV! O"$ !D M ("!N)\ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ $F"I5@C2#O*; @ 3P< !D ("! M::P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ $F"I5H!1MS$R @ U 0 !D ("!5+4 'AL+W=OG$ !;0V]N=&5N=%]4>7!E&UL4$L% 3!@ U #4 :@X ,S& $! end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 80 140 1 true 28 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation and Business Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business Note 1 - Basis of Presentation and Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Going Concern Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern Note 2 - Going Concern Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies- Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets Note 4 - Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses Note 5 - Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Common Stock Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock Note 6 - Common Stock Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stock Options Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options Note 7 - Stock Options Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Warrants Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants Note 8 - Warrants Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Selling, General and Administrative Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative Note 9 - Selling, General and Administrative Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Research and Development Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development Note 10 - Research and Development Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Related Parties Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties Note 11 - Related Parties Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Financial Instruments and Risks Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks- Note 12 - Financial Instruments and Risks Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Operating Leases Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases Note 13 - Operating Leases Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Segmented Information Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information Note 14 - Segmented Information Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies- 21 false false R22.htm 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies- 22 false false R23.htm 022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables Note 4 - Prepaid Expenses and Other Current Assets (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets 23 false false R24.htm 023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables Note 5 - Accounts Payable and Accrued Expenses (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses 24 false false R25.htm 024 - Disclosure - Note 7 - Stock Options (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables Note 7 - Stock Options (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options 25 false false R26.htm 025 - Disclosure - Note 8 - Warrants (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables Note 8 - Warrants (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants 26 false false R27.htm 026 - Disclosure - Note 9 - Selling, General and Administrative (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables Note 9 - Selling, General and Administrative (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative 27 false false R28.htm 027 - Disclosure - Note 10 - Research and Development (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables Note 10 - Research and Development (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development 28 false false R29.htm 028 - Disclosure - Note 11 - Related Parties (Tables) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables Note 11 - Related Parties (Tables) Tables http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties 29 false false R30.htm 029 - Disclosure - Note 2 - Going Concern (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual Note 2 - Going Concern (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern 30 false false R31.htm 030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables 31 false false R32.htm 031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Details 32 false false R33.htm 032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Details 33 false false R34.htm 033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Details 34 false false R35.htm 034 - Disclosure - Note 6 - Common Stock (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual Note 6 - Common Stock (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock 35 false false R36.htm 035 - Disclosure - Note 7 - Stock Options (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual Note 7 - Stock Options (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables 36 false false R37.htm 036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details Note 7 - Stock Options - Changes in Options (Details) Details 37 false false R38.htm 037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details Note 7 - Stock Options - Details of Options Outstanding (Details) Details 38 false false R39.htm 038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details Note 8 - Warrants - Schedule of Warrants (Details) Details 39 false false R40.htm 039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Details 40 false false R41.htm 040 - Disclosure - Note 10 - Research and Development - Research and Development (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details Note 10 - Research and Development - Research and Development (Details) Details 41 false false R42.htm 041 - Disclosure - Note 11 - Related Parties (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual Note 11 - Related Parties (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables 42 false false R43.htm 042 - Disclosure - Note 11 - Related Parties - Related Party Expenses (Details) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details Note 11 - Related Parties - Related Party Expenses (Details) Details 43 false false R44.htm 043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual Note 12 - Financial Instruments and Risks (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks- 44 false false R45.htm 044 - Disclosure - Note 13 - Operating Leases (Details Textual) Sheet http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual Note 13 - Operating Leases (Details Textual) Details http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases 45 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 22 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1, us-gaap:CommonStockNoParValue, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareBasic, us-gaap:PreferredStockNoParValue, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross - ovtz20230331_10q.htm 8, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 ovtz20230331_10q.htm ex_513793.htm ex_513794.htm ex_513795.htm ex_513796.htm ovtz-20230331.xsd ovtz-20230331_cal.xml ovtz-20230331_def.xml ovtz-20230331_lab.xml ovtz-20230331_pre.xml pic1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ovtz20230331_10q.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 288, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 80, "dts": { "calculationLink": { "local": [ "ovtz-20230331_cal.xml" ] }, "definitionLink": { "local": [ "ovtz-20230331_def.xml" ] }, "inline": { "local": [ "ovtz20230331_10q.htm" ] }, "labelLink": { "local": [ "ovtz-20230331_lab.xml" ] }, "presentationLink": { "local": [ "ovtz-20230331_pre.xml" ] }, "schema": { "local": [ "ovtz-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 233, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 23, "http://xbrl.sec.gov/dei/2023": 6, "total": 29 }, "keyCustom": 17, "keyStandard": 123, "memberCustom": 18, "memberStandard": 10, "nsprefix": "ovtz", "nsuri": "http://www.oculusvisiontech.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses", "menuCat": "Notes", "order": "11", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "shortName": "Note 5 - Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Common Stock", "menuCat": "Notes", "order": "12", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "shortName": "Note 6 - Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Stock Options", "menuCat": "Notes", "order": "13", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "shortName": "Note 7 - Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ClassOfWarrantOrRightTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Warrants", "menuCat": "Notes", "order": "14", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "shortName": "Note 8 - Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ClassOfWarrantOrRightTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Selling, General and Administrative", "menuCat": "Notes", "order": "15", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative", "shortName": "Note 9 - Selling, General and Administrative", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Research and Development", "menuCat": "Notes", "order": "16", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "shortName": "Note 10 - Research and Development", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Related Parties", "menuCat": "Notes", "order": "17", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "shortName": "Note 11 - Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Financial Instruments and Risks", "menuCat": "Notes", "order": "18", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "shortName": "Note 12 - Financial Instruments and Risks", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Operating Leases", "menuCat": "Notes", "order": "19", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "shortName": "Note 13 - Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "shortName": "Condensed Interim Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Segmented Information", "menuCat": "Notes", "order": "20", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "shortName": "Note 14 - Segmented Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "shortName": "Note 5 - Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 7 - Stock Options (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "shortName": "Note 7 - Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Warrants (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "shortName": "Note 8 - Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 9 - Selling, General and Administrative (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables", "shortName": "Note 9 - Selling, General and Administrative (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 10 - Research and Development (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "shortName": "Note 10 - Research and Development (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 11 - Related Parties (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "shortName": "Note 11 - Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 2 - Going Concern (Details Textual)", "menuCat": "Details", "order": "30", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual", "shortName": "Note 2 - Going Concern (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "lang": null, "name": "ovtz:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "31", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31_OwnershipAxis-ComplytrustIncMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)", "menuCat": "Details", "order": "32", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "shortName": "Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31_OwnershipAxis-ComplytrustIncMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "33", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)", "menuCat": "Details", "order": "34", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "shortName": "Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:CommonStockSharesHeldInEscrow", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 6 - Common Stock (Details Textual)", "menuCat": "Details", "order": "35", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual", "shortName": "Note 6 - Common Stock (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:CommonStockSharesHeldInEscrow", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 7 - Stock Options (Details Textual)", "menuCat": "Details", "order": "36", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual", "shortName": "Note 7 - Stock Options (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31_PlanNameAxis-RollingStockOptionPlanMember", "decimals": "1", "lang": null, "name": "ovtz:SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details)", "menuCat": "Details", "order": "37", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "shortName": "Note 7 - Stock Options - Changes in Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details)", "menuCat": "Details", "order": "38", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details", "shortName": "Note 7 - Stock Options - Details of Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details)", "menuCat": "Details", "order": "39", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details", "shortName": "Note 8 - Warrants - Schedule of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "lang": null, "name": "ovtz:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "shortName": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:FilingAndRegulatoryFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)", "menuCat": "Details", "order": "40", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "shortName": "Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:FilingAndRegulatoryFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:ResearchAndDevelopmentExpenseProjectManagement", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 10 - Research and Development - Research and Development (Details)", "menuCat": "Details", "order": "41", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details", "shortName": "Note 10 - Research and Development - Research and Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ovtz:ResearchAndDevelopmentExpenseProjectManagement", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 11 - Related Parties (Details Textual)", "menuCat": "Details", "order": "42", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "shortName": "Note 11 - Related Parties (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_RelatedPartyTransactionAxis-ReimbursementMember", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 11 - Related Parties - Related Party Expenses (Details)", "menuCat": "Details", "order": "43", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details", "shortName": "Note 11 - Related Parties - Related Party Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ConsultingFeesMember", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual)", "menuCat": "Details", "order": "44", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual", "shortName": "Note 12 - Financial Instruments and Risks (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 13 - Operating Leases (Details Textual)", "menuCat": "Details", "order": "45", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "shortName": "Note 13 - Operating Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_LeaseContractualTermAxis-VancouverCAOperatingLeaseMember", "decimals": "INF", "lang": null, "name": "ovtz:OperatingLeasesMonthlyRentExpense", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited", "shortName": "Condensed Interim Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Basis of Presentation and Business", "menuCat": "Notes", "order": "7", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "shortName": "Note 1 - Basis of Presentation and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Going Concern", "menuCat": "Notes", "order": "8", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "shortName": "Note 2 - Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "shortName": "Note 3 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ovtz20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "ovtz_ClassOfWarrantOrRightExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercisable.", "label": "ovtz_ClassOfWarrantOrRightExercisable", "verboseLabel": "Number of warrants exercisable (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisable", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "sharesItemType" }, "ovtz_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price of class of warrant or right outstanding.", "label": "ovtz_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "verboseLabel": "Warrants outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "perShareItemType" }, "ovtz_ClassOfWarrantOrRightRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining contractual term of class of warrant or right.", "label": "ovtz_ClassOfWarrantOrRightRemainingContractualTerm", "verboseLabel": "Remaining contractual life (Year)" } } }, "localname": "ClassOfWarrantOrRightRemainingContractualTerm", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "durationItemType" }, "ovtz_ClassOfWarrantOrRightTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for warrant or right.", "label": "Class of Warrant or Right [Text Block]" } } }, "localname": "ClassOfWarrantOrRightTextBlock", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants" ], "xbrltype": "textBlockItemType" }, "ovtz_CommitmentToIssueSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents commitment to issue shares.", "label": "Commitment to Issue Shares [Member]" } } }, "localname": "CommitmentToIssueSharesMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "ovtz_CommonStockSharesHeldInEscrow": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock held in escrow.", "label": "ovtz_CommonStockSharesHeldInEscrow", "terseLabel": "Common Stock, Shares Held in Escrow (in shares)" } } }, "localname": "CommonStockSharesHeldInEscrow", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "sharesItemType" }, "ovtz_ComplytrustIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents ComplyTrust Inc.", "label": "ComplyTrust Inc. [Member]" } } }, "localname": "ComplytrustIncMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "xbrltype": "domainItemType" }, "ovtz_ConsultingExpense": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred for consultation.", "label": "Consulting" } } }, "localname": "ConsultingExpense", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "ovtz_ConsultingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents consulting fees paid.", "label": "Consulting Fees [Member]" } } }, "localname": "ConsultingFeesMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "domainItemType" }, "ovtz_EmployeeStockOptionExpirationDateOfAugust12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Employee Stock Option, Expiration Date of August 1, 2024.", "label": "Employee Stock Option, Expiration Date of August 1, 2024 [Member]" } } }, "localname": "EmployeeStockOptionExpirationDateOfAugust12024Member", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_EmployeeStockOptionExpirationDateOfJuly212023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents stock option with an expiration date of July 21, 2023.", "label": "Employee Stock Option, Expiration Date of July 21, 2023 [Member]" } } }, "localname": "EmployeeStockOptionExpirationDateOfJuly212023Member", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_FilingAndRegulatoryFee": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": 0.0, "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for filing and regulatory.", "label": "Filing and regulatory fees" } } }, "localname": "FilingAndRegulatoryFee", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "ovtz_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_OperatingLeasesMonthlyRentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of monthly rent expense incurred under the operating lease.", "label": "ovtz_OperatingLeasesMonthlyRentExpense", "terseLabel": "Operating Leases, Monthly Rent Expense" } } }, "localname": "OperatingLeasesMonthlyRentExpense", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "ovtz_RangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents range five.", "label": "Range Five [Member]" } } }, "localname": "RangeFiveMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents range four.", "label": "Range Four [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_RangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents range one.", "label": "Range One [Member]" } } }, "localname": "RangeOneMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_RangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the range six.", "label": "Range Six [Member]" } } }, "localname": "RangeSixMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents range three.", "label": "Range Three [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_RangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents range two.", "label": "Range Two [Member]" } } }, "localname": "RangeTwoMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "ovtz_ReimbursementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the related party transaction for reimbursement.", "label": "Reimbursement [Member]" } } }, "localname": "ReimbursementMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_ResearchAndDevelopmentExpenseBusinessDevelopment": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details": { "order": 2.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to business development.", "label": "Business development" } } }, "localname": "ResearchAndDevelopmentExpenseBusinessDevelopment", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details" ], "xbrltype": "monetaryItemType" }, "ovtz_ResearchAndDevelopmentExpensePayroll": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details": { "order": 3.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to payroll.", "label": "Payroll" } } }, "localname": "ResearchAndDevelopmentExpensePayroll", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details" ], "xbrltype": "monetaryItemType" }, "ovtz_ResearchAndDevelopmentExpenseProjectManagement": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details": { "order": 0.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to project management.", "label": "Project management" } } }, "localname": "ResearchAndDevelopmentExpenseProjectManagement", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details" ], "xbrltype": "monetaryItemType" }, "ovtz_RollingStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the Rolling Stock Option Plan.", "label": "Rolling Stock Option Plan [Member]" } } }, "localname": "RollingStockOptionPlanMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of research and development expenses.", "label": "Schedule of Research and Development Expenses [Table Text Block]" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables" ], "xbrltype": "textBlockItemType" }, "ovtz_ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of selling, general and administrative expenses.", "label": "Schedule of Selling, General and Administrative Expenses [Table Text Block]" } } }, "localname": "ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables" ], "xbrltype": "textBlockItemType" }, "ovtz_ScheduleOfWarrantsOrRightTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's warrants or rights.", "label": "Schedule of Warrants or Right [Table Text Block]" } } }, "localname": "ScheduleOfWarrantsOrRightTableTextBlock", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables" ], "xbrltype": "textBlockItemType" }, "ovtz_SellingGeneralAndAdministrativeDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for selling, general and administrative expenses.", "label": "Selling, General and Administrative Disclosure [Text Block]" } } }, "localname": "SellingGeneralAndAdministrativeDisclosureTextBlock", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative" ], "xbrltype": "textBlockItemType" }, "ovtz_SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of issued and outstanding common shares reserved in a share-based compensation.", "label": "ovtz_SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved", "terseLabel": "Share-based Compensation Arrangement, Percent of Issued and Outstanding Common Shares Reserved" } } }, "localname": "SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "percentItemType" }, "ovtz_SharebasedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share-based compensation.", "label": "Share-based Compensation [Member]" } } }, "localname": "SharebasedCompensationMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "domainItemType" }, "ovtz_VancouverCAOperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the operating lease for the Vancouver, Candada location.", "label": "Vancouver, CA Operating Lease [Member]" } } }, "localname": "VancouverCAOperatingLeaseMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_VestingEverySixMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the options vested every 6 months.", "label": "Vesting Every Six Months [Member]" } } }, "localname": "VestingEverySixMonthsMember", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "ovtz_WarrantsExpiringOnApril192023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants expiring on April 19, 2023.", "label": "Warrants Expiring on April 19, 2023 [Member]" } } }, "localname": "WarrantsExpiringOnApril192023Member", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "domainItemType" }, "ovtz_WarrantsExpiringOnJune42025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants expiring on June 4, 2025.", "label": "Warrants Expiring on June 4, 2025 [Member]" } } }, "localname": "WarrantsExpiringOnJune42025Member", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "domainItemType" }, "ovtz_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of difference between Current Assets and Current Liabilities.", "label": "ovtz_WorkingCapitalDeficit", "terseLabel": "Working Capital (Deficit)" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.oculusvisiontech.com/20230331", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "ovtz_statement-statement-note-10-research-and-development-research-and-development-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Research and Development - Research and Development (Details)" } } }, "localname": "statement-statement-note-10-research-and-development-research-and-development-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-10-research-and-development-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Research and Development" } } }, "localname": "statement-statement-note-10-research-and-development-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-11-related-parties-related-party-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Related Parties - Related Party Expenses (Details)" } } }, "localname": "statement-statement-note-11-related-parties-related-party-expenses-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-11-related-parties-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Related Parties" } } }, "localname": "statement-statement-note-11-related-parties-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)" } } }, "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-3-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" } } }, "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets" } } }, "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-5-accounts-payable-and-accrued-expenses-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Accounts Payable and Accrued Expenses" } } }, "localname": "statement-statement-note-5-accounts-payable-and-accrued-expenses-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-7-stock-options-changes-in-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options - Changes in Options (Details)" } } }, "localname": "statement-statement-note-7-stock-options-changes-in-options-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-7-stock-options-details-of-options-outstanding-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options - Details of Options Outstanding (Details)" } } }, "localname": "statement-statement-note-7-stock-options-details-of-options-outstanding-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-7-stock-options-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options" } } }, "localname": "statement-statement-note-7-stock-options-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-8-warrants-schedule-of-warrants-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Warrants - Schedule of Warrants (Details)" } } }, "localname": "statement-statement-note-8-warrants-schedule-of-warrants-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-8-warrants-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Warrants" } } }, "localname": "statement-statement-note-8-warrants-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)" } } }, "localname": "statement-statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-note-9-selling-general-and-administrative-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Selling, General and Administrative" } } }, "localname": "statement-statement-note-9-selling-general-and-administrative-tables", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "ovtz_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.oculusvisiontech.com/20230331", "xbrltype": "stringItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "totalLabel": "Accounts Payable and Accrued Liabilities, Current" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r361" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccountsPayableCurrent", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued fees and expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r379" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r2", "r8", "r20", "r241", "r244", "r263", "r284", "r285", "r380", "r381", "r382", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r50", "r361", "r429" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r217", "r218", "r219", "r297", "r386", "r387", "r388", "r420", "r432" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r37", "r38", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r213", "r224" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation (Note 7)", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r70", "r82", "r102", "r131", "r137", "r142", "r150", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r236", "r238", "r250", "r276", "r318", "r361", "r371", "r390", "r391", "r425" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r184", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r23", "r81", "r355" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r23", "r59", "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r59" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "verboseLabel": "Exercise price (in CAD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "verboseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r43", "r277", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r386", "r387", "r420", "r428", "r432" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common stock, no par value (in dollars per share)", "terseLabel": "Common Stock, No Par Value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r49", "r306" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r49", "r306", "r324", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r49", "r278", "r361" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 at December 31,2022 and March 31,2023" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r21", "r86", "r88", "r94", "r273", "r282" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "auth_ref": [ "r9", "r40" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r39", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r57" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "negatedTotalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r181", "r183", "r214", "r215", "r216", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r95", "r110", "r111", "r112", "r113", "r114", "r118", "r119", "r121", "r122", "r123", "r125", "r248", "r249", "r274", "r283", "r358" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r422" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of foreign currency translation" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r10", "r78", "r90", "r91", "r92", "r105", "r106", "r107", "r109", "r115", "r117", "r126", "r151", "r152", "r180", "r217", "r218", "r219", "r234", "r235", "r240", "r241", "r242", "r243", "r244", "r245", "r247", "r255", "r256", "r257", "r258", "r259", "r260", "r263", "r284", "r285", "r286", "r297", "r346" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58", "r328" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": 2.0, "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Office and administration" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r6", "r31" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r155", "r156", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r156", "r331" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r89", "r228", "r229", "r230", "r231", "r232", "r233", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r22", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r42", "r377" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Tax Receivable \u2013 Canadian GST" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r5" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (decrease) in accounts payable and accrued expenses due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r96", "r97", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r54", "r71", "r280", "r361", "r383", "r389", "r421" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r80", "r102", "r150", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r237", "r238", "r239", "r250", "r361", "r390", "r425", "r426" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "terseLabel": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": 3.0, "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "ComplyTrust Inc." } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r59", "r60", "r61" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r56", "r61", "r72", "r79", "r84", "r87", "r92", "r102", "r108", "r110", "r111", "r112", "r113", "r116", "r117", "r120", "r131", "r136", "r141", "r144", "r150", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r249", "r250", "r281", "r326", "r344", "r345", "r359", "r370", "r390" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "us-gaap_NetIncomeLoss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonrelatedPartyMember": { "auth_ref": [ "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Party not related to reporting entity.", "label": "Nonrelated Party [Member]" } } }, "localname": "NonrelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r423" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": 1.0, "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Rent", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r46", "r68", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r3", "r55", "r252", "r253", "r254" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Currency translation differences", "verboseLabel": "Currency translation differences" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r4", "r7", "r69", "r85", "r88" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r48", "r392" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, no par value (in dollars per share)" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r48", "r306" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r48", "r167" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r378" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid Expense and Other Assets, Current" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r83", "r153", "r154", "r356" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r370", "r430", "r431" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": 4.0, "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "auth_ref": [ "r103", "r104", "r267", "r268", "r269", "r270", "r300", "r301", "r302", "r303", "r304", "r323", "r325", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by related and nonrelated party status.", "label": "Related and Nonrelated Party Status [Axis]" } } }, "localname": "RelatedAndNonrelatedPartyStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "auth_ref": [ "r103", "r104", "r267", "r268", "r269", "r270", "r300", "r301", "r302", "r303", "r304", "r323", "r325", "r365" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated party status.", "label": "Related and Nonrelated Party Status [Domain]" } } }, "localname": "RelatedAndNonrelatedPartyStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r103", "r104", "r267", "r268", "r269", "r270", "r300", "r301", "r302", "r303", "r304", "r323", "r325", "r353" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r41", "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related party transactions", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r267", "r268", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r264", "r265", "r266", "r268", "r271", "r294", "r295", "r296", "r329", "r330", "r331", "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r44", "r226", "r427" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "totalLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r45", "r419" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details": { "order": 1.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Software development" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r73", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r66", "r279", "r287", "r288", "r293", "r307", "r361" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r78", "r105", "r106", "r107", "r109", "r115", "r117", "r151", "r152", "r217", "r218", "r219", "r234", "r235", "r240", "r242", "r243", "r245", "r247", "r284", "r286", "r297", "r432" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r93", "r102", "r132", "r133", "r135", "r139", "r140", "r146", "r148", "r149", "r150", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r250", "r275", "r390" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r11", "r12", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r130", "r131", "r134", "r138", "r142", "r143", "r144", "r145", "r146", "r147", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative (Note 8)", "totalLabel": "Selling, General and Administrative Expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Add back non-cash share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "verboseLabel": "Number of options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, aggregate intrinsic value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Options outstanding (in shares)", "periodStartLabel": "Options outstanding (in shares)", "verboseLabel": "Number of options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "verboseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r184", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r181", "r187", "r206", "r207", "r208", "r209", "r212", "r220", "r221", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "verboseLabel": "Remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "us-gaap_SharesIssued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r62", "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r10", "r19", "r78", "r90", "r91", "r92", "r105", "r106", "r107", "r109", "r115", "r117", "r126", "r151", "r152", "r180", "r217", "r218", "r219", "r234", "r235", "r240", "r241", "r242", "r243", "r244", "r245", "r247", "r255", "r256", "r257", "r258", "r259", "r260", "r263", "r284", "r285", "r286", "r297", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r105", "r106", "r107", "r126", "r272", "r291", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r321", "r322", "r323", "r325", "r327", "r328", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r365" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r126", "r272", "r291", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r321", "r322", "r323", "r325", "r327", "r328", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r365" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230331/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230331/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r49", "r52", "r53", "r63", "r308", "r324", "r347", "r348", "r361", "r371", "r383", "r389", "r421", "r432" ], "calculation": { "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r65", "r101", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r180", "r246", "r349", "r351", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-6-common-stock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-2-going-concern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230331/role/statement-note-9-selling-general-and-administrative-tables" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r74", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230331/role/statement-note-7-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r362", "r363", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r118", "r123" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average number of common shares outstanding - basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.oculusvisiontech.com/20230331/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r373": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r374": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r375": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4M", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org//985-730/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 65 0001437749-23-013198-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-013198-xbrl.zip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end